PoonM.A., O'ConnelM.J., MoertelC.G.: Biochemical modulation of Fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol., 7: 1407–1408, 1989.
2.
PoonM.A., O'ConnellM.J., WieandH.S.: Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967–1972, 1991.
3.
BurokerT.R., O'ConnellM.J., WieandH.S.: Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J. Clin. Oncol., 12: 14–20, 1994.
4.
Allen MershT., EarlamS., FordyC.: Quality of life and survival with continuous hepatic artery floxuridine infusion for colorectal liver metastases. Lancet, 344: 1255–1260, 1994.
5.
SheithauerW., RosenH., KornekG.V., SebestaC., DepishD.: Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. British Med. J., 306: 752–755, 1993.
6.
KemenyN.: Chemotherapy for colorectal carcinoma: one small step forward, one step backward. J. Clin. Oncol., 13: 1287–1290, 1995.
7.
PetrelliN.J.: It is time to statify with prognostic factors for hepatic metastases. J. Clin. Oncol., 13: 2471–2472, 1995.
8.
Nordic Gastrointestinal tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. J. Clin. Oncol., 10: 904–911, 1992.
9.
SobreroA.F., AscheleC., BertinoJ.R.: Fluorouracil in colorectal cancer: a tale of two drugs. Implications for biochemical modulation. Clin. Oncol., 15: 368–381, 1997.
10.
Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol., 10: 896–903, 1992.
11.
Advanced Colorectal Cancer Meta-Analysis Project: Meta-Analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J. Clin. Oncol., 12: 960–969, 1994.
12.
MarshJ.C., BertinoJ.R., DavisC.A.: The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol., 9: 371–380, 1991.
13.
LokichJ.J., AhlgrenJ.D., GulloJ.J.: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J. Clin. Oncol., 7: 425–432, 1989.
14.
ArdalanB., ChuaL., TianE.: A phase II study of weekly 24 hour infusion with high dose 5-fluorouracil with leucovorin in colorectal carcinoma J. Clin. Oncol., 9: 625–630, 1991.
15.
LeichmanC.G., LeichmanL., SpearsC.P.: Prolonged infusion of fluorouracil with weekly bolus leucovorin: a phase II study in patients with disseminated colorectal cancer. J. Natl. Cancer Inst., 85: 41–44, 1993.
16.
LouvetC., De GramontA., BennamounM.: High dose folinic acid, 5-Fluorouracil bolus and continuous infusion in metastatic colorectal cancer: a 3-day/3-week schedule. Eur. J. Cancer, 28: 611–612, 1992.
